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Abstract Tumor cells frequently have pronounced effects on the skeleton including bone destruction, bone pain,
hypercalcemia, and depletion of bone marrow cells. Despite the serious sequelae associated with skeletal metastasis,
the mechanisms by which tumor cells alter bone homeostasis remain largely unknown. In this study, we tested the
hypothesis that the disruption of bone homeostasis by tumor cells is due in part to the ability of tumor cells to upregulate
osteopontin (OPN) mRNA in osteoblasts. Conditioned media were collected from tumor cells that elicit either osteolytic
(MCF-7, PC-3) or osteoblastic responses (LNCaP) in animal models and their effects on OPN gene expression were
compared using an osteoblast precursor cell line, MC3T3-E1 cells. Secretory products from osteolytic but not
osteoblastic tumor cell lines were demonstrated to upregulate OPN in osteoblasts while inhibiting osteoblast prolifer-
ation and differentiation. Signal transduction studies revealed that regulation of OPN was dependent on both protein
kinase C (PKC) and the mitogen-activated protein (MAP) kinase cascade. These results suggest that the upregulation of
OPN may play a key role in the development of osteolytic lesions. Furthermore, these results suggest that drugs that
prevent activation of the MAP kinase pathway may be efficacious in the treatment of osteolytic metastases. J. Cell.
Biochem. 78:607–616, 2000. © 2000 Wiley-Liss, Inc.
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The ability of prostate and breast cancer
cells to preferentially metastasize to bone has
been recognized for more than 50 years, yet the
mechanisms governing this process have not
been firmly established. Attachment of tumor
cells to bone marrow endothelium [Haq et al.,
1992] and to bone matrix proteins [Hullinger et
al., 1998], growth factor support of tumor cells
provided by bone stromal and osteoblast cells
[Gleave et al., 1991; Iwamura et al., 1993; Lang
et al., 1995; Ritchie et al., 1997], and upregu-
lation of specific bone-associated proteins in
tumor cells (bone sialoprotein [Bellahcene et
al., 1996] and osteopontin [Behrend et al.,
1994]) all have been implicated in the patho-
genesis of skeletal metastasis. Although we are
beginning to gain insight into the pathogenesis
of skeletal metastasis, and early detection of
breast and prostate cancers may reduce the
frequency of metastatic disease, skeletal me-
tastasis remains a serious problem with devas-
tating consequences. Tumor cells frequently
have pronounced effects on the structure and
function of the skeleton including bone destruc-
tion, abnormal bone formation, bone pain, hy-
percalcemia, and depletion of bone marrow
cells.
Despite the serious sequelae associated with
skeletal metastasis, the mechanisms by which
tumor cells exert their effects on bone architec-
ture remain largely unknown. These effects in-
clude an osteolytic response with breast cancer
invasion, and osteoblastic as well as osteolytic
changes observed in response to prostate can-
cer metastasis [Sharpe and McDonald, 1942].
Previous research suggests that tumor cells do
not resorb or form bone directly, rather they
alter bone homeostasis by influencing the func-
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tion of osteoblasts and/or osteoclasts [Boyde et
al., 1986]. Indeed, breast cancer cells have been
demonstrated to affect osteoblast proliferation
[Evans et al., 1991; Siwek et al., 1997], and
prostate cancer cells have been demonstrated
to alter osteoblast gene expression and prolif-
eration [Noda et al., 1988; Kido et al., 1997].
The ability of tumor cells to regulate gene
expression in osteoblasts is an important ob-
servation because secretion of the bone-
associated extracellular matrix glycoproteins,
osteopontin (OPN) and bone sialoprotein
(BSP), may play a pivotal role in the regulation
of bone homeostasis. Existing evidence sug-
gests that normal bone homeostasis requires
intracellular signaling or coupling between os-
teoblasts and osteoclasts [Howard et al., 1981].
Although the dynamics of this coupling process
are not completely understood, OPN, which is
synthesized and secreted by osteoblasts, has
been demonstrated to trigger signal transduc-
tion processes in osteoclasts [Miyauchi et al.,
1991] and to potentiate osteoclast-mediated
bone resorption [Ross et al., 1993]. Thus, OPN
may play an important role in the response of
bone to tumor cell invasion, with elevated lev-
els of OPN leading to pathologic activation of
osteoclasts, thereby resulting in a net loss of
bone.
Therefore, we hypothesized that the osteo-
lytic response of bone to tumor cell invasion is
due in part to the ability of tumor cells to
upregulate OPN gene transcription, transla-
tion, and subsequent secretion by osteoblasts,
resulting in enhanced osteoclast activity. To
begin to test this hypothesis, conditioned me-
dia were collected from human breast and pros-
tate cancer cells that elicit either osteolytic
(MCF-7, PC-3) or osteoblastic responses (LN-
CaP) in bone [Yoneda et al., 1994; Soos et al.,
1997] and compared for their effects on OPN
gene expression in a well-characterized osteo-
blast precursor cell line, MC3T3-E1 cells
[Franceschi and Iyer, 1992; Franceschi et al.,
1994]. Results demonstrated that secretory
products from tumor cell lines that trigger an
osteolytic response in bone not only increased
levels of OPN transcript in osteoblasts but also
inhibited osteoblast differentiation and prolif-
eration, whereas tumor cells that trigger an
osteoblastic response did not inhibit osteoblast
differentiation or alter levels of OPN tran-
script. Signal transduction studies demon-
strated that PKC and the MAP kinase cascade
were involved in tumor cell–mediated upregu-
lation of OPN. Collectively, these results sug-
gest that tumor cell–induced osteolysis may be
due to both inhibitory effects on osteoblasts
and stimulatory effects on osteoclasts via en-
hanced OPN secretion by osteoblasts. Further-
more, these results suggest that PKC antago-




PC-3 cells, isolated from a vertebral metas-
tasis of a human prostate cancer patient in
1978 [Kaighn et al., 1979], were obtained from
American Type Culture Collection (Rockville,
MD) and maintained in RPMI containing 10%
fetal bovine serum (FBS), 100 U/ml penicillin,
and 100 mg/ml streptomycin. LNCaP cells were
isolated in 1977, from a patient with prostate
adenocarcinoma [Horoszewicz et al., 1980].
Disseminated bony metastases were found on
the bone scan, with metastasis to lymph nodes
also noted. The LNCaP cell line was estab-
lished from a supraclavicular lymph node le-
sion. LNCaP cells and LNCaP sublines (C4 and
C4-2 cells) were obtained from UroCor, Inc.
(Oklahoma City, OK) and maintained in
T-media containing 5% FBS, 100 U/ml penicil-
lin, and 100 mg/ml streptomycin as outlined by
UroCor. MCF-7 cells were established from a
pleural effusion obtained from a patient with
metastatic breast cancer and were estrogen re-
sponsive [Lippman et al., 1976]. MCF-7 cells
were acquired from Dr. Steve Ethier (Univer-
sity of Michigan, Ann Arbor, MI) and main-
tained in RPMI containing 10% FBS, 100 U/ml
penicillin, and 100 mg/ml streptomycin.
MC3T3-E1 cells are preosteoblasts derived
from murine calvaria. When treated with
ascorbate, these cells express osteoblast-
specific markers and are capable of producing a
mineralized matrix [Franceschi and Iyer, 1992;
Franceschi et al., 1994]. MC3T3-E1 cells were
obtained from Dr. Renny T. Franceschi (Uni-
versity of Michigan, Ann Arbor, MI) and were
maintained in modified Eagle’s medium
(MEM) containing 10% FBS, 100 U/ml penicil-
lin, and 100 mg/ml streptomycin. (All culture
reagents were purchased from Gibco/BRL Life
Technologies, Grand Island, NY).
608 Hullinger et al.
Conditioned Media
Cancer cells were grown to 80–90% conflu-
ency in their respective media containing 10%
FBS (5% FBS for LNCaP cells). The media
were removed and the cells were washed with
phosphate-buffered saline. Cells were incu-
bated for 24 h in serum free media. After 24 h,
conditioned media were collected and protease
inhibitors were added [10 mM leupeptin, 0.8
nM aprotinin, 28 mM phenylmethyl-sulfonyl
fluoride (Sigma Chemical Co., St. Louis, MO)].
Conditioned media were concentrated with a
Biomax centrifugal filter device (MW cutoff 10
kD, Millipore Corp., Bedford, MA), and then
frozen and lyophilized. Nonconditioned media
containing protease inhibitors were concen-
trated and lyophilized for use as a vehicle con-
trol. Before use, lyophilized media were rehy-
drated in water and protein concentration was
determined by the Lowry method (BioRad DC
protein assay kit, Bio-Rad Laboratories, Her-
cules, CA).
RNA Extraction and Northern Analysis
Total RNA was extracted from MC3T3-E1
cells using a modified guanidinium isothiocya-
nate procedure [Xie and Rothblum, 1991]. To-
tal RNA (20 mg) was separated electrophoreti-
cally in a 1% agarose–5% formaldehyde gel.
RNA was then transferred to a Duralon-UV
membrane (Stratagene, La Jolla, CA) and im-
mobilized by UV crosslinking. Membranes
were hybridized overnight at 42°C with 32P
cDNA probes for mouse OPN, BSP (both pro-
vided by Marian F. Young, National Institute
of Dental Research, Bethesda, MD [Young et
al., 1990; Young et al., 1994]), osteocalcin
(OCN) [Celeste et al., 1986] and glyceraldehyde
phosphate dehydrogenase. After a wash at
high stringency, the blots were exposed to Xo-
mat film (Eastman Kodak Co., Rochester, NY)
at 270°C.
Protein Extraction and Western Blotting
Proteins were extracted from MC3T3-E1
cells with a 1% Triton X-100 lysis buffer con-
taining 20 mM HEPES (pH 7.4), 50 mM NaCl,
1 mM EGTA, 5 mM b-glycerophosphate, 30
mM sodium pyrophosphate, and 100 mM so-
dium orthovanadate. Immediately before use,
protease inhibitors were added (10 mM leupep-
tin, 0.8 nM aprotinin, 28 mM phenylmethyl-
sulfonyl fluoride, all reagents from Sigma
Chemical Co.). After a 10-min lysis time, dishes
were scraped and extracts were centrifuged for
2 min at 6,000 g. Supernatants were collected
and protein concentration determined by the
Lowry method (BioRad DC protein assay kit).
One hundred microgram protein samples were
separated electrophoretically in a 10% sodium
dodecyl sulfate (SDS) polyacrylamide gel and
transferred to polyvinylidene fluoride mem-
branes (Millipore Corp). Equal loading was
verified with Ponceau S Solution (Sigma), and
the blots were then probed with Anti-ACTIVE
MAPK pAb V6671 (Promega, Madison, WI),
which recognizes the dually phosphorylated
form of ERK1 and ERK2. Blots were then
washed and probed with goat anti-rabbit per-
oxidase conjugated antibody (Gibco BRL) for
chemiluminescence detection (ECL, Amer-
sham Life Science, Arlington Heights, IL).
Differentiation Assay
The initial assay was designed as follows:
MC3T3-E1 cells were plated in 60-mm dishes
at 50,000 cells/cm2 and incubated overnight in
10% FBS-containing media. The following day,
designated as day 0, the media were removed
and replaced with 2% FBS-containing media
plus 50 mg/ml ascorbate, to promote osteoblast
differentiation, and conditioned media (CM) or
vehicle at 25 mg/ml (dose selected from dose–
response experiments). Media and CM were
changed on days 2 and 4. RNA was harvested
on day 5 and analyzed for markers of osteoblast
differentiation by Northern analysis. In se-
lected situations, the experimental design was
as above, except CM was not added until day 4.
To determine the time course of the CM re-
sponse, MC3T3-E1 cells were incubated in 2%
FBS-containing media plus CM (no ascorbate)
and RNA collected at 30 min, 3 h, 12 h, and
24 h. Differentiation experiments were con-
ducted on at least three separate occasions.
Antibody and Signal Transduction Reagents
Twenty-four-hour responses of cells to PC-3
CM were also evaluated in the presence of a
blocking antibody to transforming growth fac-
tor beta (100 mg/ml, anti-TGFb1,2,3, Genzyme,
Cambridge, MA). Twenty-four hour responses
of cells to PC-3 CM were also evaluated after
pretreatment of MC3T3-E1 cells with the MEK
(MAPK/ERK kinase) inhibitor PD98059, or the
PKC inhibitor GF109203X.
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Growth Assays
Proliferation assay
MC3T3-E1 cells were plated in 24-well
plates at 50,000 cells/cm2 and incubated over-
night in 10% FBS–containing media. The fol-
lowing day, designated as day 0, the media
were removed and replaced with 2% FBS–
containing media plus 25 mg/ml PC-3 or
MCF-7. Media and CM were changed every
48 h. Cell number was assessed with a Coulter
counter (Coulter Corp., Miami, FL) on days
1,3,5,10 and 15. Counts were measured on trip-
licate samples, and experiments were per-
formed on two separate occasions.
DNA synthesis assay
MC3T3-E1 cells were plated in 24-well
plates at 50,000 cells/cm2 and incubated over-
night in 10% FBS–containing media. The fol-
lowing day, designated as day 0, media were
removed and replaced with 2% FBS–
containing media plus 25 mg/ml PC-3 or MCF-7
cm. Media and CM were changed every 48 h for
7 days. Three microcuries per milliliter
[methyl-3H]thymidine (40–60 Ci/mmol, Amer-
sham Life Science, Arlington Heights, IL) were
added for the final 2 h of incubation. Cells were
washed and precipitated in 5% trichloroacetic
acid (TCA) at 4°C for 1 h. TCA solution was
removed and cells were dissolved in 1% lauryl
sulfate (SDS) at 55°C for 1 h. The SDS solution
plus two water washes were combined and
counted using a liquid scintillation counter
(Wallac 1410, Pharmacia, Sweden) [Franceschi
et al., 1985]. Counts were measured on tripli-
cate samples and experiments were performed
on two separate occasions.
RT-PCR
Total RNA from PC-3, MCF-7, and C4-2
cells was used for reverse transcriptase poly-
merase chain reaction (RT-PCR) screening.
Briefly, 1 mg of total RNA or water, as a
negative control, was incubated in 10X RT
buffer, 25 mM dXTP mix, 3.0 mg oligo d(T),
and M-MLV RT for 1 h at 38°C. Then the
product was incubated in 10X Taq/RT buffer,
1 mM dXTP mix, 500 ng of each sense and
antisense oligonucleotide, and Taq polymer-
ase [AmpliTaq Polymerase, Perkin Elmer Ce-
tus, Norwalk, CT (all other reagents from
GIBCO-BRL, Gaithersburg, MD)]. Primer
sequences used were as follows: bone morpho-
genetic protein-4 (BMP-4), 59 GCC-ATT-CCG-
TAG-TGC-CAT-CC, 39 AAA-TAC-TCC-AAT-
ACT-TCG-GG [Oida et al., 1995]; TGFb1, 59
ACC-ACT-GCC-GCA-CAA-CTC-CGG-TGA-C,
39 ATC-TAT-GAC-AAG-TTC-AAG-CAG-
AGT-A [Derynck et al., 1985]. Amplification
was accomplished with 35 cycles at 94°C/72°C
(Perkin Elmer Cetus DNA thermal cycler).
PCR products were then separated electro-
phoretically in a 3% agarose DNA gel and
stained with ethidium bromide.
Statistics
The unpaired t-test (two-tailed; P , 0.05)
was used to compare mean experimental val-
ues with the corresponding control values as
described in the figure legends.
RESULTS
Effects of Conditioned Media on Osteoblast
mRNA Levels
As demonstrated in Figure 1, MC3T3-E1
cells grown in the presence of ascorbate alone
expressed typical osteoblast markers at day 5
of differentiation: OPN, OCN, and BSP. How-
ever, when these cells were treated with ascor-
bate plus CM on days 0, 2, and 4 during the
5-day differentiation period, the levels of these
markers changed. CM from the osteolytic cell
lines, PC-3 and MCF-7, resulted in increased
OPN mRNA levels, whereas OCN and BSP
levels decreased. In contrast, CM from the os-
teoblastic LNCaP and LNCaP subclones (C4
and C4-2 cells) had no discernible effect on any
of the markers assessed. Non-CM controls for
each cell line (RPMI and T-medium) had no
effect on osteoblast transcripts when compared
to ascorbate-treated controls. Shown in Figure
1 are the results for nonconditioned RPMI con-
trol (used for MCF-7 and PC-3 cells). Similar
results were observed when a single treatment
of CM was added on day 4 of the 5-day differ-
entiation period (data not shown).
Effects of CM on MC3T3-E1 Cell Proliferation
The ability of PC-3 and MCF-7 CM to alter
proliferation of MC3T3-E1 cells was deter-
mined during a 15-day period. PC-3 CM was
observed to significantly reduce cell number on
days 3, 5, 10, and 15. MCF-7 CM significantly
reduced cell number on days 10 and 15. In
addition, PC-3 and MCF-7 CM significantly re-
duced thymidine incorporation when compared
to control on day 7 (results not shown).
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PC-3 CM Mediated Upregulation of OPN Is
MEK and PKC Dependent
The activation state of ERK1 and ERK2 in
MC3T3-E1 cells after treatment with PC-3 CM
exposure was assessed. As shown in Figure 2,
PC-3 CM treatment resulted in a rapid and
transient activation of both ERK1 and ERK2
as indicated by the appearance of the dually
phosphorylated form of these kinases within 15
min and the decrease of activated kinases
within 30 min.
As demonstrated in Figure 3, pretreatment
of MC3T3-E1 cells with the MEK inhibitor
PD98059 inhibited the PC-3 CM-mediated in-
crease in OPN mRNA in a dose–response fash-
ion. To confirm that the MEK inhibitor blocked
the activation of MAP kinases, MC3T3-E1 cells
were pretreated for 30 min with PD98059 fol-
lowed by PC-3 CM. As shown in Figure 2,
PD98059 blocked PC-3 CM-induced activation
of both ERK1 and ERK2 at all time points
assessed.
TPA (phorbol 12-myristate 13-acetate) was
used to evaluate the effect of PKC activation on
OPN expression in MC3T3-E1 cells. TPA treat-
ment increased OPN mRNA levels in
MC3T3-E1 cells (data not shown). In addition,
TPA treatment activated the MAP kinase
pathway, as indicated by a rapid and prolonged
activation of ERK1 and ERK2 (Fig. 2). As dem-
onstrated in Figure 2, activation of the MAP
kinase pathway by TPA was PKC dependent as
the PKC inhibitor, GF109203X, dramatically
reduced the levels of activated ERK proteins.
GF109203X was demonstrated to block PC-3
CM-induced upregulation of OPN in a dose–
response fashion, with 30 mM being the most
efficacious concentration. As shown in Figure 4,
pretreatment with 30 mM GF109203X com-
pletely abolished the upregulation of OPN by
PC-3 CM. Pretreatment of MC3T3-E1 cells with
30 mM GF109203X also blocked PC-3 CM-
induced activation of both ERK1 and ERK2 at
each time point assessed (Fig. 2).
Fig. 1. Northern blot analysis of MC3T3-E1 cells at day 5 of differentiation with continuous exposure to condi-
tioned media (CM). Lanes 1–5 and 6–9 represent two separate experiments. MC3T3-E1 cells were treated with 50
mg/ml ascorbate plus CM or vehicle at 25 mg/ml. Blots were probed for osteopontin (OPN), osteocalcin (OCN), bone
sialoprotein (BSP), and glyceraldehyde phosphate dehydrogenase (GAPDH) to evaluate loading. Treatments were as
follows: ascorbate only (control), LNCaP CM, LNCaP subclone, C4 CM, LNCaP subclone, C4-2 CM, MCF-7 CM,
PC-3 CM, and PC-3/MCF-7 CM vehicle (vehicle).
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Potential Mediators of the OPN Response
The RT-PCR technique was used to compare
mRNAs from PC-3 and MCF-7 cells, which
triggered similar OPN responses, with mRNAs
from the LNCaP subclone C4-2 cells, which
revealed no discernable effect on osteoblast
gene expression. This study focused on two po-
tential regulators of OPN expression in osteo-
blasts: TGFb and bone morphogenic protein-4
(BMP-4). The PCR results demonstrated that
PC-3 and MCF-7 cells expressed mRNAs for
both TGFb and BMP-4, whereas the LNCaP
subclone C4-2 did not express TGFb, with
weak expression of BMP-4 (Fig. 5). In experi-
ments not shown, both TGFb and BMPs were
demonstrated to upregulate OPN in MC3T3-E1
cells.
DISCUSSION
Previous studies have demonstrated that the
prostate cancer cell line PC-3 and the breast
cancer cell line MCF-7 produce osteolytic le-
sions when these cells are present in bone,
whereas the prostate cancer cell line LNCaP
elicits osteoblastic changes when present in
bone [Yoneda et al., 1994; Soos et al., 1997].
Although there is great interest in the mecha-
nisms by which tumor cells elicit these differ-
ing responses in bone, much of the recent re-
search on the mechanisms involved has
focused on the effects of tumor cell factors di-
rectly on osteoblasts or osteoclasts without ad-
dressing the effects on signaling between osteo-
blasts and osteoclasts. In this study, we have
focused on the regulation of a potentially im-
portant coupling molecule, OPN, by tumor
cells.
OPN is an extracellular matrix glycoprotein
found in a variety of tissues with many pro-
posed physiologic functions (for review see
[Butler et al., 1996]). A primary characteristic
of OPN is the ability to promote cell migration
and attachment via an Arg-Gly-Asp amino acid
sequence [Xuan et al., 1994, 1995]. In bone,
OPN is synthesized by osteoblasts and is
known to promote the attachment of and trig-
ger signal transduction processes in osteoclasts
[Miyauchi et al., 1991]. In addition, OPN has
Fig. 2. Effects of MEK and PKC inhibition on TPA and PC-3 conditioned media (CM)-induced activation of ERKs in
MC3T3-E1 cells. All MC3T3-E1 cells were cultured in media containing 2% FBS during the experiment (control, lane
1). Some cells were also pre-treated for 30 min with the MEK inhibitor PD98059 (PD, 30 mM) or the PKC inhibitor
GF109203X (GF, 30 mM). Cells were then treated with 50 mg/ml PC-3 CM or 100 nM TPA. Proteins were then
extracted at 5, 15, and 30 min posttreatment. Blots were probed with an antibody to the dually phosphorylated form
of ERK1 and ERK2.
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been demonstrated to potentiate osteoclast-
mediated bone resorption [Ross et al., 1993].
Although OPN has been implicated in the ma-
lignancy of tumor cells in vivo [Behrend et al.,
1994], and plasma concentrations of OPN are
elevated in patients with metastatic disease
[Senger et al., 1989], the role of OPN as a
potential coupling molecule involved in the os-
teolytic response of bone to tumor cell invasion
has not been evaluated. Therefore, we hypoth-
esized that the osteolytic response of bone to
tumor cell invasion is due to the ability of tu-
mor cells to upregulate OPN mRNA levels in
osteoblasts, ultimately resulting in enhanced
osteoclast-mediated bone resorption.
This hypothesis was tested by comparing the
effects of secretory products from tumor cell
lines, which elicit contrasting responses in bone,
on OPN expression in a well-characterized osteo-
blast precursor cell line—MC3T3-E1 cells. Previ-
ous studies have established that ascorbate in-
duces the differentiation of MC3T3-E1 cells
into mature osteoblasts, which produce a min-
Fig. 3. Effect of MEK inhibition on PC-3 conditioned media (CM) induced upregulation of osteopontin (OPN) in
MC3T3-E1 cells. All cells were cultured in media containing 2% fetal bovine serum during the experiment (control,
lane 1). Several plates were also pretreated for 30 min with the MEK inhibitor PD98059 (PD, 1, 10, or 30 mM). Cells
were then treated with 25 mg/ml PC-3 CM for 24 h and analyzed for OPN mRNA levels. (18 S RNA shown for
loading).
Fig. 4. Effect of PKC inhibition on PC-3 conditioned media
(CM) induced upregulation of OPN in MC3T3-E1 cells. All cells
were cultured in 60-mm dishes at 50,000 cells/cm2 with media
containing 2% fetal bovine serum during the experiment (con-
trol, lane 1). Some cells were also pre-treated for 30 min with
the PKC inhibitor GF109203X (GF, 30mM). Cells were then
treated with 25 mg/ml PC-3 CM for 24 h. and analyzed for OPN
mRNA levels. (18 S RNA shown for loading).
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eralized matrix in vitro [Franceschi and Iyer,
1992; Franceschi et al., 1994]. During the mat-
uration process, these cells express markers
characteristic of osteoblasts such as type I col-
lagen, alkaline phosphatase, and OPN and, im-
portantly, the osteoblast specific markers, BSP
and OCN [Franceschi and Iyer, 1992; France-
schi et al., 1994].
Results from the present study clearly demon-
strate that secretory products from the tumor cell
lines that induce osteolytic lesions, PC-3 and
MCF-7, upregulate OPN in MC3T3-E1 cells,
whereas secretory products from a cell line that
elicits bone formation, LNCaP, had no effect on
levels of OPN in MC3T3-E1 cells (Fig. 1). Al-
though additional tumor and osteoblast cell lines
need to be evaluated in future studies, these find-
ings, coupled with the ability of OPN to activate
osteoclasts [Miyauchi et al., 1991] and potenti-
ate osteoclast-mediated bone resorption [Ross
et al., 1993], support our hypothesis and sug-
gest that OPN may play an important role in
the pathogenesis of tumor-induced osteolytic
lesions. Interestingly, Ross et al. demonstrated
that soluble OPN competed with native OPN in
bone, thereby blocking the attachment of oste-
oclasts to bone. This finding raises the possibil-
ity that tumor-induced upregulation of OPN
may inhibit osteoclast activity. However, we
propose that the OPN secreted by osteoblasts
becomes incorporated on the surface of bone, as
occurs under normal conditions, and acts as an
additional adhesive/activation substrate for os-
teoclasts.
Although it is apparent from the present
study as well as several others [Perkel et al.,
1990; Evans et al., 1991; Lacroix et al., 1996;
Martinez et al., 1996; Kido et al., 1997; Siwek
et al., 1997] that tumor-derived factors have
direct effects on osteoblast differentiation and
proliferation, and these direct effects likely in-
fluence the response of bone to tumor cell inva-
sion, we propose that the effects on coupling
processes are equally important to consider
when studying the dynamics of tumor-induced
disruption of bone homeostasis. In support of
this concept, it has been suggested that breast
cancer cells interact with osteoblasts to sup-
port osteoclast formation [Thomas et al., 1999].
Given that tumor cell–induced upregulation
of OPN in osteoblasts may be involved in the
development of osteolytic lesions and thus a
relevant therapeutic target, we studied the sig-
nal transduction pathway involved in this pro-
cess. As demonstrated in Figure 2, PC-3 CM
induced a rapid and transient activation of the
MAP kinase pathway consistent with growth
factor–induced activation [Chao et al., 1994;
Reiss et al., 1997]. As revealed in Figure 3,
PC-3 CM-induced upregulation of OPN was de-
pendent on the activation of the MAP kinase
pathway as the MEK inhibitor PD98059 [Lazar
et al., 1995] blocked the upregulation of OPN.
Furthermore, the results revealed that PKC is
a key upstream mediator of the OPN response
because the PKC inhibitor GF109203X [Reiss
et al., 1997] completely abolished activation of
the MAP kinase pathway and the upregulation
of OPN (Figs, 2 and 4). These findings are in
agreement with previous studies, which dem-
onstrate that phorbol esters upregulate OPN
via PKC [Smith and Denhardt, 1989; Atkins et
al., 1997; Tucker et al., 1998]. In addition,
these results demonstrate that PKC and the
MAP kinase pathway are involved in the reg-
ulation of OPN in response to a physiologic
factor(s) secreted by tumor cells.
Fig. 5. Reverse transcriptase polymerase chain reaction (RT-
PCR) detection of mRNAs for transforming growth factor beta
(TGFb1), and bone morphogenic protein 4 (BMP-4). Total RNA
extracted from C4-2 cells, PC-3 cells, and MCF-7 cells at 80–
90% confluency was reverse transcribed and amplified by PCR.
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To determine whether a known factor was
mediating the CM induced regulation of OPN,
the RT-PCR technique was used to compare
RNAs from tumor cell lines that upregulated
OPN with RNAs from a cell line that did not
alter OPN levels. As shown in Figure 5, PC-3
and MCF-7 cells contained transcripts for
TGFb1 and BMP-4. These findings are sup-
ported by Harris et al., who demonstrated tran-
scripts for TGFb, and BMP-2, 3, and 4 in PC-3
cells [Harris et al., 1994]. Previous studies
have demonstrated that TGFb and BMPs in-
duce responses in osteoblasts similar to those
observed in the present study [Noda et al.,
1988; Vukicevic et al., 1990; Lecanda et al.,
1997]. However, further studies are required to
determine whether these specific factors, as
well as others, are responsible for CM-induced
upregulation of OPN mRNA in osteoblasts.
Currently, few therapeutics are available for
the treatment of skeletal complications associ-
ated with breast and prostate cancer. Fortu-
nately, the bisphosphonates are emerging as
efficacious agents for their ability to both in-
hibit metastasis formation in bone [Sasaki et
al., 1998] and reduce the frequency of morbid
skeletal events in patients with metastatic
breast cancer [Body et al., 1998]. Presumably,
the beneficial effects of bisphosphonates result
from their inhibitory actions on osteoclast-
mediated bone resorption, thereby reducing
bone degradation and the subsequent release
of bone matrix–associated growth factors. The
results provided in the present study suggest
that drugs that inhibit PKC may also be effec-
tive in patients with metastatic disease via
similar mechanisms.
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